Skip to content
Respiratory Health Protocol

Lung Support

Upload template

Protocol development in integrative medicine is not typically a simple process. Individuals require individualized care, and what works for one patient may not work for another.

To establish these protocols, we first developed a Rating Scale that could be used to discern the rigor of evidence supporting a specific nutrient’s therapeutic effect.

The following protocols were developed using only A through C-quality evidence.

Systematic review or meta-analysis of human trials
RDBPC human trials
2+ studies and/or 1 study with 50 + subjects
RDBPC human trials
1 study


200-340 mg, total per day of magnesium citrate, minimum 12 weeks2,3

  • Magnesium has shown to improve FEV11,2
  • The simultaneous long-term administration of magnesium citrate and drug (bronchodilator) in asthmatic children has been shown to be beneficial in the management of asthma3
  • Bronchial reactivity induced by methacholine was decreased by magnesium oral supplementation. It was also shown that magnesium provided better management of the symptoms in pediatric patients with moderate asthma4
  • PEFR increased by 5.8% in addition to an improvement in AQLQ and ACQ2
Magnesium citrate in the Fullscript catalog

Fish oil 

1.8 g EPA 1.3 g DHA, total per day, minimum 21 days6

  • EPA and DHA alter the 15-LOX pathway and the subsequent metabolic profile7
  • Omega-3 polyunsaturated fatty acids (PUFAs) decreased airway inflammation markers like 9α, 11β-PGF26
  • The introduction of PUFAs reduced the prevalence of child asthma5
Fish oil in the Fullscript catalog

Vitamin C

500-1500 mg, total per day of ascorbic acid, minimum 2 weeks8,9,10

  • A protective effect was observed in exercise-induced asthma patients9,10
  • An improvement in post-exercise FEV1, LTC4-E4, 9α, 11β-PGF2 and FENO concentrations were observed in addition to an amelioration in asthma symptom scores10
Vitamin C in the Fullscript catalog


The Fullscript Integrative Medical Advisory team has developed or collected these protocols from practitioners and supplier partners to help health care practitioners make decisions when building treatment plans. By adding this protocol to your Fullscript template library, you understand and accept that the recommendations in the protocol are for initial guidance and may not be appropriate for every patient.

Upload template


Systematic review or meta-analysis of human trials
Systematic review or meta-analysis of human trials

Fullscript content philosophy

At Fullscript, we are committed to curating accurate, and reliable educational content for practitioners and patients alike. Our educational offerings cover a broad range of topics related to integrative medicine, such as supplement ingredients, diet, lifestyle, and health conditions.

Medically reviewed by expert practitioners and our internal Integrative Medical Advisory team, all Fullscript content adheres to the following guidelines:

  1. In order to provide unbiased and transparent education, information is based on a research review and obtained from trustworthy sources, such as peer-reviewed articles and government websites. All medical statements are linked to the original reference and all sources of information are disclosed within the article.
  2. Information about supplements is always based on ingredients. No specific products are mentioned or promoted within educational content.
  3. A strict policy against plagiarism is maintained; all our content is unique, curated by our team of writers and editors at Fullscript. Attribution to individual writers and editors is clearly stated in each article.
  4. Resources for patients are intended to be educational and do not replace the relationship between health practitioners and patients. In all content, we clearly recommend that readers refer back to their healthcare practitioners for all health-related questions.
  5. All content is updated on a regular basis to account for new research and industry trends, and the last update date is listed at the top of every article.
  6. Potential conflicts of interest are clearly disclosed.